Tempus AI (NASDAQ:TEM) Announces Earnings Results

Tempus AI (NASDAQ:TEM) posted its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10, FiscalAI reports. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.

Tempus AI Stock Performance

NASDAQ:TEM traded up $2.74 during mid-day trading on Thursday, reaching $44.29. 7,303,011 shares of the company’s stock were exchanged, compared to its average volume of 5,879,973. Tempus AI has a one year low of $40.77 and a one year high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The business’s fifty day simple moving average is $51.49 and its two-hundred day simple moving average is $52.92. The firm has a market capitalization of $7.95 billion, a PE ratio of -25.75 and a beta of 3.46.

Insider Activity

In related news, CAO Ryan M. Bartolucci sold 4,116 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $181,392.12. Following the sale, the chief accounting officer owned 74,041 shares of the company’s stock, valued at $3,262,986.87. This represents a 5.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 11,529 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $634,095.00. Following the transaction, the chief financial officer owned 114,866 shares in the company, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 449,793 shares of company stock worth $23,248,231. Insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. Victory Capital Management Inc. increased its holdings in Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after buying an additional 162 shares during the period. SeaCrest Wealth Management LLC increased its stake in Tempus AI by 3.7% in the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after acquiring an additional 229 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Tempus AI by 64.5% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 653 shares of the company’s stock valued at $53,000 after purchasing an additional 256 shares in the last quarter. Pathstone Holdings LLC lifted its stake in Tempus AI by 1.4% during the third quarter. Pathstone Holdings LLC now owns 18,338 shares of the company’s stock worth $1,480,000 after purchasing an additional 261 shares during the last quarter. Finally, Kestra Advisory Services LLC boosted its holdings in shares of Tempus AI by 4.7% in the 4th quarter. Kestra Advisory Services LLC now owns 7,278 shares of the company’s stock valued at $430,000 after purchasing an additional 324 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of Tempus AI in a research note on Friday, July 24th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Finally, Lake Street Capital lowered Tempus AI to a “hold” rating in a report on Monday, July 20th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus target price of $68.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.